Sophiris Bio Inc. Banner Image

Sophiris Bio Inc.

  • Ticker SPHS
    Exchange NASDAQ More
  • Industry Drugs - Generic More
  • Sector Healthcare More
Sophiris Bio Inc. Logo Image
  • 1-10 Employees
  • Based in La Jolla, California
Sophiris Bio Inc. is a late-stage clinical biopharmaceutical company developing topsalysin (PRX302) for the treatment of patients with urological diseases. Topsalysin is in Phase 2 clinical development for the focal treatment of localized prostate cancer as well as Phase 3 clinical development for the treatment of the lower urinary tract symptoms of benign prostatic hyperplasia (BPH). TopsalysinMore is a highly potent ablative agent that is selective and targeted in that it is only activated by enzymatically active PSA which is found in high concentrations in the transition zone of the prostate and in and around prostate tumor cells.
4.8 / 5.0 (210)

Sophiris Bio Inc. reports have an aggregate usefulness score of 4.8 based on 210 reviews.

Sophiris Bio Inc.

Most Recent Annual Report

Sophiris Bio Inc.
MOST RECENT 2018 Annual Report and Form 10K

Sophiris Bio Inc. does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.

Request Information

Older/Archived Annual Reports

Sophiris Bio Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!